BrainsWay (XTAE:BWAY) E10: ₪-0.88 (As of Mar. 2026)


XTAE:BWAY BrainsWay Ltd XTAE:BWAY
70 GF Score
Price ₪45.17
GF Value ₪22.01
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is BrainsWay E10?

BrainsWay XTAE:BWAY -0.94% 70 E10 is ₪-0.88 as of Mar. 2026. GuruFocus rates XTAE:BWAY with a GF Score™ of 70/100 and a GF Value™ of ₪22.01 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

BrainsWay's adjusted earnings per share data for the three months ended in Mar. 2026 was ₪0.181. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₪-0.88 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-10), BrainsWay's current stock price is ₪45.17. BrainsWay's E10 for the quarter that ended in Mar. 2026 was ₪-0.88. BrainsWay's Shiller PE Ratio of today is .


BrainsWay  (XTAE:BWAY) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


BrainsWay E10 Related Terms


BrainsWay E10 Historical Data

* Premium members only.

The historical data trend for BrainsWay's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BrainsWay E10 Chart

BrainsWay Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -1.22 0.00 -0.91

BrainsWay Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.03 -1.00 -0.99 -0.91 -0.88

XTAE:BWAY vs ABT, SYK, MDT: E10 Comparison

For the Medical Devices subindustry, BrainsWay's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BrainsWay Shiller PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BrainsWay's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BrainsWay's Shiller PE Ratio falls into.


XTAE:BWAY
70GF Score
BrainsWay Ltd XTAE:BWAY
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BrainsWay E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BrainsWay's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.181/330.2130*330.2130
=0.181

Current CPI (Mar. 2026) = 330.2130.

BrainsWay Quarterly Data

per share eps CPI Adj_EPS
201606 0.181 241.018 0.248
201609 -0.120 241.428 -0.164
201612 -0.331 241.432 -0.453
201703 -0.391 243.801 -0.530
201706 -0.090 244.955 -0.121
201709 -0.361 246.819 -0.483
201712 -0.572 246.524 -0.766
201803 -0.181 249.554 -0.240
201806 -0.361 251.989 -0.473
201809 -0.271 252.439 -0.354
201812 -0.422 251.233 -0.555
201903 -0.331 254.202 -0.430
201906 -0.512 256.143 -0.660
201909 -0.361 256.759 -0.464
201912 -0.301 256.974 -0.387
202003 -0.452 258.115 -0.578
202006 -0.090 257.797 -0.115
202009 -0.120 260.280 -0.152
202012 -0.060 260.474 -0.076
202103 -0.151 264.877 -0.188
202106 -0.181 271.696 -0.220
202109 -0.151 274.310 -0.182
202112 -0.120 278.802 -0.142
202203 -0.151 287.504 -0.173
202206 -0.211 296.311 -0.235
202209 -0.452 296.808 -0.503
202212 -0.361 296.797 -0.402
202303 -0.211 301.836 -0.231
202306 -0.151 305.109 -0.163
202309 -0.030 307.789 -0.032
202312 0.012 306.746 0.013
202403 0.000 312.332 0.000
202406 0.060 314.175 0.063
202409 0.060 315.301 0.063
202412 0.000 315.605 0.000
202503 0.060 319.799 0.062
202506 0.151 322.561 0.155
202509 0.120 324.800 0.122
202512 0.211 324.054 0.215
202603 0.181 330.213 0.181

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₪-0.88 mean?
BrainsWay (XTAE:BWAY) has a E10 of ₪-0.88 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on BrainsWay and its competitors.
Is BrainsWay's E10 too high?
BrainsWay's current E10 is ₪-0.88. Overall, BrainsWay has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BrainsWay's E10 compare to ABT and SYK?
BrainsWay's E10 of ₪-0.88 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Medical Devices & Instruments company?
A good E10 depends on the Medical Devices & Instruments industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on BrainsWay and its competitors. BrainsWay's current E10 is ₪-0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrainsWay stock overvalued right now?
Based on GuruFocus' analysis, BrainsWay (XTAE:BWAY) is currently considered Significantly Overvalued. The stock's GF Value™ is ₪22.01, compared to a current price of ₪45.17 — trading 105.2% above its estimated fair value. The current E10 is ₪-0.88. BrainsWay's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For BrainsWay (XTAE:BWAY), the current E10 is ₪-0.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BrainsWay (XTAE:BWAY) Overvalued in 2026?

Based on GuruFocus' analysis, BrainsWay stock appears to be overvalued. The current stock price of ₪45.17 is trading 105.2% above its estimated GF Value™ of ₪22.01. GuruFocus considers BrainsWay to be Significantly Overvalued.

Key valuation signals for XTAE:BWAY:

  • E10: ₪-0.88
  • GF Value™: ₪22.01 vs. price of ₪45.17 (105.2% above fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the XTAE:BWAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BrainsWay Business Description

Other Exchanges BWAY:USA
Address 16 Hartum Street, 14th Floor, RAD Tower, Har HaHotzvim, Jerusalem, ISR, 9777516
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
70GF Score

Get the complete analysis for XTAE:BWAY

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪45.17
Price
₪22.01
GF Value